Utilization of TAS-102 (TAS) or regorefenib (Rego) among commercially insured refractory metastatic colorectal cancer (R-mCRC) patients.

被引：0
|
作者：
Zheng, Hanke
Yu, Tianzhou
Romley, John
Barzi, Afsaneh
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
[2] City Hope AccessHope, Med Oncol & Therapeut, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e23121
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
    Fujii, Hironori
    Matsuhashi, Nobuhisa
    Kitahora, Mika
    Takahashi, Takao
    Hirose, Chiemi
    Iihara, Hirotoshi
    Yamada, Yunami
    Watanabe, Daichi
    Ishihara, Takuma
    Suzuki, Akio
    Yoshida, Kazuhiro
    ONCOLOGIST, 2020, 25 (03): : E469 - E476
  • [42] Analysis retrospective from efficacy with TAS-102 in patients with metastatic colorectal cancer refractory: Experience at two hospitals
    Beatriz, Gonzalez-Astorga
    Cebrian Irene, Gonzalez
    Ma Teresa, Delgado Urena
    Veronica, Conde
    Carmen, Sanchez-Toro
    Javier, Garcia-Garcia
    Encarnacion, Gonzalez-Flores
    ANNALS OF ONCOLOGY, 2017, 28
  • [43] Real-world data of TAS-102 therapy in refractory metastatic colorectal cancer (mCRC): The experience of the University Hospital of Montreal (CHUM).
    El Khoury, Reem
    Tehfe, Jad
    Ouellet, Marie
    Aubin, Francine
    Lougnarath, Rasmy
    Ayoub, Jean-Pierre M.
    Tehfe, Mustapha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 137 - 137
  • [44] Effect of regorafenib and TAS-102 in metastatic colorectal cancer (mCRC) patients on survival in salvage line with different toxicity profile.
    Sugimoto, Naotoshi
    Yoshinami, Tetsuhiro
    Yamamoto, Sachiko
    Yagi, Toshinari
    Imamura, Fumio
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [45] Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States
    Cho, Sang Kyu
    Hay, Joel W.
    Barzi, Afsaneh
    CLINICAL COLORECTAL CANCER, 2018, 17 (04) : E751 - E761
  • [46] A phase 1b expansion study of TAS-102 with oxaliplatin for refractory metastatic colorectal cancer
    Cecchini, Michael
    Kortmansky, Jeremy S.
    Cui, Can
    Wei, Wei
    Thumar, Jaykumar Ranchobdhai
    Uboha, Nataliya, V
    Hafez, Navid
    Lacy, Jill
    Fischbach, Neal A.
    Sabbath, Kert D.
    Gomez, Christina M.
    Sporn, Jonathan Reed
    Stein, Stacey
    Hochster, Howard S.
    CANCER, 2021, 127 (09) : 1417 - 1424
  • [47] A Systematic Review and Network Meta-Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer
    Sonbol, Mohamad Bassam
    Benkhadra, Raed
    Wang, Zhen
    Firwana, Belal
    Walden, Daniel J.
    Mody, Kabir
    Hubbard, Joleen M.
    Murad, M. Hassan
    Ahn, Daniel H.
    Bekaii-Saab, Tanios
    ONCOLOGIST, 2019, 24 (09): : 1174 - 1179
  • [48] Real world aspects of palliative trifluridine plus tiperacil (TAS-102) in refractory metastatic colorectal cancer
    Wallander, Mikael
    Rolander, Bo
    Avall-Lundqvist, Elisabeth
    Elander, Nils O.
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2020, 11 (04) : 616 - +
  • [49] A systematic review and network meta analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer.
    Sonbol, Mohamad Bassam
    Benkhadra, Raed
    Wang, Zhen
    Firwana, Belal
    Mody, Kabir
    Kasi, Pashtoon Murtaza
    Hubbard, Joleen Marie
    Murad, M. Hassan
    Ahn, Daniel H.
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [50] Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.
    Zhang, Wu
    Suenaga, Mitsukuni
    Schirripa, Marta
    Cao, Shu
    Yang, Dongyun
    Berger, Martin D.
    West, Jordan David
    Ning, Yan
    Wakatsuki, Takeru
    Mashima, Tetsuo
    Okazaki, Satoshi
    Miyamoto, Yuji
    Hanna, Diana L.
    Marmorino, Federica
    Salvatore, Lisa
    Moretto, Roberto
    Borelli, Beatrice
    Barzi, Afsaneh
    Loupakis, Fotios
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345